Compare AbCellera Biologics Inc (ABCL) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Wynn Resorts, Limited — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while Wynn Resorts, Limited trades at $97.6 (market cap $10.00B). The key difference: Wynn Resorts, Limited is far larger — about 4.3× AbCellera Biologics Inc's market cap, and Wynn Resorts, Limited pays a 1.04% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | WYNN | |
|---|---|---|
Market Cap | $2.35B | $10.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $133.34 |
52-Week Low | $2.78 | $94.78 |
Enterprise Value | $1.99B | $20.36B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Wynn Resorts (WYNN) trades at $96.35, up 0.46% on the day, with a bearish technical signal and recent earnings misses. Revenue reached $7.14B in 2025, but net income declined to $327M, reflecting margin pressure. Analyst consensus remains strongly bullish with a $136.22 price target, though high debt and competitive headwinds persist. The company announced Q2 2026 earnings for August 4, 2026, with investor focus on Macau and Las Vegas performance.
The stock presents a contrarian opportunity given analyst optimism amid technical weakness. Upside hinges on earnings recovery and debt management, but risks include geopolitical tensions in Macau and sustained margin compression. Current valuation at P/E 27.47 may limit near-term gains without profit improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
